文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

通过调控VEGF信号传导促进早产儿视网膜病变周边视网膜血管化扩展

Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
PubMed 文献 · Am J Ophthalmol · 2023-12-22

这项回顾性非随机治疗比较研究纳入2019年1月至2022年12月筛查的早产儿,比较双眼玻璃体腔注射贝伐珠单抗(0.25 mg)治疗的1型早产儿视网膜病变(ROP)眼与胎龄和出生体重匹配的较轻ROP对照眼。P=.003),支持抗VEGF调控可促进发育性血管生成向周边无血管视网膜扩展。

要点

  • 治疗组随访期间颞侧血管扩展量显著大于对照组(872±521 vs 253±151像素,P=.003)。
  • 基线时治疗组颞侧血管范围有短于对照组的趋势(3667±547 vs 4262±937像素,P=.084),随访时两组无差异(P=.945)。
  • 作者认为临床证据支持抗VEGF调控VEGF信号可促进发育性血管生成向周边无血管视网膜扩展。

核心结论

  • 临床证据支持实验室研究结果,即使用玻璃体腔抗VEGF药物调控VEGF可增加ROP中发育性血管生成向周边无血管视网膜的扩展,同时抑制病理性玻璃体腔内血管生成。

研究设计与样本

  • 研究为回顾性、非随机治疗比较,在学术机构开展,研究人群为2019年1月至2022年12月筛查ROP的所有早产儿。
  • 实验组为接受双侧贝伐珠单抗0.25 mg治疗的1型ROP眼,需由认证眼科摄影师在治疗2周内及之后1至3周两次检查中获得充分眼底成像。
  • 对照组为胎龄和出生体重匹配、ROP严重程度轻于1型ROP的婴儿。
  • 主要结局指标为由设盲分析者测量的治疗眼与对照眼颞侧视网膜血管范围,采用配对和非配对t检验。

主要发现

  • 382例筛查婴儿中34例发生1型ROP,实验组11例、对照组11例。
  • 基线时治疗组颞侧血管范围有短于对照组的趋势(3667±547 vs 4262±937像素,95%CI -1277,88;P=.084)。
  • 随访时两组颞侧血管范围无差异(P=.945)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Experimental studies provide evidence that regulation of VEGF receptor-2 signaling in endothelial cells orders cell divisions and extends developmental angiogenesis while inhibiting pathologic intravitreal angiogenesis and has relevance to retinopathy of prematurity (ROP). We tested the hypothesis that intravitreal anti-VEGF would extend vascularization into peripheral avascular retina in human type 1 ROP compared with controls. DESIGN: Retrospective, nonrandomized treatment comparison. METHODS: The study was conducted at an academic institution, with the study population comprising all premature infants screened for ROP from January 2019 through December 2022. The experimental group included type 1 ROP treated with bilateral bevacizumab (0.25 mg) and had adequate fundus imaging by a certified ophthalmic photographer at 2 examinations: within 2 weeks of treatment and 1-3 weeks later. A control group included gestational age- and birthweight-matched infants with ROP less severe than type 1 ROP. The main outcome measure was extent of temporal retinal vasculature measured by a masked analyst between treated and control eyes. Paired and nonpaired t tests were used. RESULTS: Of 382 screened infants, 34 developed type 1 ROP; 11 comprised the experimental group and 11 the control group. At baseline, there was a trend toward shorter temporal vascular extent in treatment compared with control groups (3667±547 vs 4262±937 pixels, 95% CI -1277, 88; P = .084) but no difference between groups at follow-up (P = .945). Vascular extension was significantly greater in the treatment than control (872±521 vs 253±151 pixels, 95% CI 262, 977; P = .003), showing catch-up growth. CONCLUSIONS: This clinical evidence supports laboratory-based studies that regulation of VEGF using an intravitreal anti-VEGF agent increases developmental angiogenesis into the peripheral avascular retina while inhibiting pathologic intravitreal angiogenesis in ROP.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sauer L, Chandler M, Hartnett ME, et al. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling. Am J Ophthalmol. 2023. PMID: 38141904. doi:10.1016/j.ajo.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。